Can This AI Stock Bounce Back in 2026?

Artificial intelligence (AI) is all the rage on Wall Street these days, but not every AI stock is equally successful. Some of ...

Recursion’s First AI Clinical Proof Links Pipeline Progress With Valuation Gap

Recursion Pharmaceuticals (NasdaqGS:RXRX) reports its first AI enabled clinical proof of concept in familial adenomatous polyposis. The company advances five clinical programs, signaling broader use ...

A Look At Recursion Pharmaceuticals (RXRX) Valuation After AI Milestone And Improved Quarterly Results

Recursion Pharmaceuticals (RXRX) is back in focus after reporting fourth quarter and full year 2025 results, highlighting much higher quarterly revenue, a smaller net loss, and fresh commentary on its ...
Hosted on MSN

Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA's AI Favorite?

Recursion Pharmaceuticals' (NASDAQ: RXRX) stock price has seen a dramatic increase, not due to company-specific news or drug announcements, but rather due to actions taken by artificial intelligence ...

Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...

BoFA Lowers PT on Recursion Pharmaceuticals (RXRX), Keeps a Hold Rating

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Low Risk Penny Stocks to Buy Now. On February 27, Bank of America ...
Seeking Alpha

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Kyiv, Ukraine and Salt Lake City, UT, April 09, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced ...
AOL

Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock?

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...
Insider Monkey

Recursion Pharmaceuticals Reports Positive Phase 1b/2 TUPELO Trial Results, Validating AI-Driven Therapy for FAP

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the AI stocks under $20 to buy now. On December 8, Recursion Pharmaceuticals announced positive Phase 1b/2 results from its ongoing TUPELO trial ...

Recursion Pharmaceuticals’ Earnings Call Highlights AI Momentum

Recursion Pharmaceuticals, Inc ( (RXRX)) has held its Q4 earnings call. Read on for the main highlights of the call.
Yahoo

Recursion Pharma's AI-powered therapy reduces polyp growth in a rare disease trial

Dec 8 (Reuters) - Recursion Pharma, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in ...
Seeking Alpha

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs Platform will ...